Skip to content
Peptidepedia

Thymosin Alpha 1 Side Effects: Safety Profile, Risks & What to Expect (2026)

From Peptidepedia, the trusted peptide wiki.

Side Effects

Thymosin Alpha 1 demonstrates an exceptional safety profile across clinical trials and decades of therapeutic use. Reported adverse effects are generally mild and infrequent.

Common (1-10%): Injection site reactions including transient erythema, mild pain, or induration. These typically resolve within 24-48 hours and diminish with continued use.

Uncommon (<1%): Mild fatigue, headache, or muscle aches during initial treatment, potentially reflecting immune activation. Low-grade fever has been reported rarely.

Rare: Allergic reactions are exceedingly rare given the peptide's endogenous nature. No serious adverse events have been attributed to Ta1 in controlled clinical trials.

Contraindications: Individuals with organ transplants on immunosuppressive therapy should avoid Ta1 due to theoretical risks of graft rejection from enhanced immune function. Those with autoimmune conditions should exercise caution and consult healthcare providers, though Ta1's immunomodulatory (rather than purely immunostimulatory) nature may actually benefit certain autoimmune states.

Frequently Asked Questions

Unlike pure immunostimulants, Thymosin Alpha 1 demonstrates immunomodulatory properties that include tolerance-promoting effects. Clinical evidence does not suggest increased autoimmune risk, and some research indicates potential benefit in certain autoimmune conditions through immune rebalancing.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Goldstein AL, et al. Thymosin alpha 1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci USA. 1977.
  2. Romani L, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through Toll-like receptor signaling. Blood. 2004.
  3. Garaci E, et al. Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application. Int J Immunopharmacol. 2000.
  4. Wu J, et al. Thymosin alpha 1 treatment reduces mortality in severe sepsis patients. Crit Care. 2013.
  5. Chien RN, et al. Thymosin alpha 1 in the treatment of chronic hepatitis B: a randomized controlled trial. Hepatology. 1998.
  6. You J, et al. Meta-analysis: thymalfasin for chronic hepatitis B. Aliment Pharmacol Ther. 2009.
  7. Andreone P, et al. Thymosin alpha 1 plus interferon alpha for hepatitis C. J Viral Hepat. 2006.
  8. Garaci E, et al. Thymosin alpha 1 in cancer treatment. Ann N Y Acad Sci. 2010.
  9. Gravenstein S, et al. Augmentation of influenza antibody response in elderly men by thymosin alpha 1. J Am Geriatr Soc. 1989.
  10. Tuthill C, et al. Thymalfasin: biological properties and clinical applications. Int Immunopharmacol. 2010.
←Read the full Thymosin Alpha 1 guide

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”